Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

This study has been terminated.
(License termination.)
Sponsor:
Information provided by:
Thallion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00735332
First received: August 13, 2008
Last updated: August 4, 2010
Last verified: August 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: October 2010
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)